Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333340 | 0.91 | HRH3 (0.61) | CCR5CCR3USP30HRH3MCHR1 | |
| SCHEMBL8738665 | 0.87 | JAK2 (0.58) | CCR5CCR3USP30KMT2AMEN1 | |
| SCHEMBL9001749 | 0.86 | CCR3 (0.51) | CCR5CCR3USP30 | |
| SCHEMBL3840449 | 0.86 | CCR3 (0.51) | CCR5CCR3USP30 | |
| SCHEMBL25498560 | 0.86 | LMNA (0.65) | CCR5USP30POLBHRH3ADORA2A | |
| SCHEMBL12082859 | 0.86 | PDK2 (0.61) | CCR5HTR2AHTR2CHRH3JAK2 | |
| SCHEMBL1164100 | 0.84 | MCHR1 (0.50) | CCR5USP30HRH3ADORA2AADORA1 | |
| SCHEMBL1448084 | 0.84 | MCHR1 (0.47) | CCR5USP30HRH3ADORA2AADORA1 | |
| SCHEMBL94337 | 0.84 | MCHR1 (0.50) | CCR5USP30HRH3ADORA2AADORA1 | |
| SCHEMBL16553814 | 0.84 | HTR2A (0.54) | CCR5USP30HTR2AHTR2CHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | claimed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | claimed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240308992-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Biopolar Youtang(Guangdong) Pharmaceutical Co., Ltd. (CN) | 2024-09-19 | — | — | US | disclosed |
| EP-4431508-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Biopolar Youtang (Guangdong) Pharmaceutical Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-118201922-A | Drak2 inhibitor and preparation method and application thereof | 百极优棠(广东)医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024035194-A1 | NOVEL HETEROARYL-SUBSTITUTED DERIVATIVE AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, CANCER, AND INFLAMMATORY DISEASE COMPRISING SAME | 환인제약 주식회사 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023083330-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 百极优棠(广东)医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2861577-B1 | TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-01-04 | — | — | EP | disclosed |
| EP-2471787-A1 | New compounds | Boehringer Ingelheim International GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-2027107-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007132010-A1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| US-7122565-B2 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT LLC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1326853-B1 | THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| CN-1639141-A | Novel thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER LAMBERT CO (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1326853-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002028847-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | CCR5 3124/4885CCR3 4449/4885USP30 4534/4885 |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | CCR5 4599/4885CCR3 4385/4885USP30 3576/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CCR5 2552/4885CCR3 2380/4885USP30 2814/4885 |
| US-20240308992-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VRK2, MAPKAPK2, DAPK2 | CCR5 2040/4885CCR3 4584/4885USP30 4400/4885 |
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE3B, PDE7A | CCR5 308/4885CCR3 437/4885USP30 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.